Values as of: 2024-11-03
COMMON STOCK | Medical Devices |
Last Closing
USD 82.4Change
0.00 (0.00)%Market Cap
USD 4.17BVolume
1.82MAnalyst Target
USD 21.00Verdict
Verdict
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Company Website : https://www.transmedics.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| DXCM | DexCom Inc |
N/A |
USD 27.48B |
| PODD | Insulet Corporation |
N/A |
USD 16.52B |
| BRKR | Bruker Corporation |
N/A |
USD 8.98B |
| MASI | Masimo Corporation |
N/A |
USD 7.71B |
| PRCT | Procept Biorobotics Corp |
N/A |
USD 4.99B |
| AXNX | Axonics Modulation Technologie.. |
N/A |
USD 3.60B |
| NARI | Inari Medical Inc |
N/A |
USD 2.85B |
| LIVN | LivaNova PLC |
N/A |
USD 2.80B |
| QDEL | Quidel Corporation |
N/A |
USD 2.62B |
| IRTC | iRhythm Technologies Inc |
N/A |
USD 2.37B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| FFTY | Innovator IBD® 50 ETF | 0.00 % | 0.80 % |
N/A |
N/A |
| CIB0:XETRA | VanEck Bionic Engineering.. | 0.00 % | 0.00 % |
N/A |
USD 4.90M |
| CYBG:LSE | VanEck Bionic Engineering.. | 0.00 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 4.40% | 49% | F | 51% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 4.40% | 49% | F | 51% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 93.34% | 59% | D- | 78% | C+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 93.34% | 59% | D- | 78% | C+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 325.84% | 84% | B | 87% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 325.84% | 84% | B | 87% | B+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 79.91% | 87% | B+ | 91% | A- | ||
| Dividend Return | 79.91% | 87% | B+ | 91% | A- | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 91.29% | 40% | F | 23% | F | ||
| Risk Adjusted Return | 87.53% | 99% | N/A | 94% | A | ||
| Market Capitalization | 4.17B | 95% | A | 87% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
